S&P 500   2,750.62 (+3.43%)
DOW   23,433.16 (+3.44%)
QQQ   200.69 (+2.18%)
AAPL   266.43 (+2.70%)
FB   174.04 (+3.08%)
MSFT   165.68 (+1.34%)
GOOGL   1,211.37 (+2.44%)
AMZN   2,036.99 (+1.26%)
CGC   15.13 (+4.34%)
BABA   195.05 (-1.49%)
MU   48.36 (+3.89%)
GE   7.30 (+3.84%)
TSLA   546.97 (+0.28%)
AMD   48.83 (+2.67%)
T   29.72 (-1.20%)
ACB   0.87 (+7.45%)
NFLX   370.81 (-0.55%)
BAC   23.38 (+5.55%)
GILD   74.69 (+0.03%)
DIS   100.76 (-0.47%)
S&P 500   2,750.62 (+3.43%)
DOW   23,433.16 (+3.44%)
QQQ   200.69 (+2.18%)
AAPL   266.43 (+2.70%)
FB   174.04 (+3.08%)
MSFT   165.68 (+1.34%)
GOOGL   1,211.37 (+2.44%)
AMZN   2,036.99 (+1.26%)
CGC   15.13 (+4.34%)
BABA   195.05 (-1.49%)
MU   48.36 (+3.89%)
GE   7.30 (+3.84%)
TSLA   546.97 (+0.28%)
AMD   48.83 (+2.67%)
T   29.72 (-1.20%)
ACB   0.87 (+7.45%)
NFLX   370.81 (-0.55%)
BAC   23.38 (+5.55%)
GILD   74.69 (+0.03%)
DIS   100.76 (-0.47%)
S&P 500   2,750.62 (+3.43%)
DOW   23,433.16 (+3.44%)
QQQ   200.69 (+2.18%)
AAPL   266.43 (+2.70%)
FB   174.04 (+3.08%)
MSFT   165.68 (+1.34%)
GOOGL   1,211.37 (+2.44%)
AMZN   2,036.99 (+1.26%)
CGC   15.13 (+4.34%)
BABA   195.05 (-1.49%)
MU   48.36 (+3.89%)
GE   7.30 (+3.84%)
TSLA   546.97 (+0.28%)
AMD   48.83 (+2.67%)
T   29.72 (-1.20%)
ACB   0.87 (+7.45%)
NFLX   370.81 (-0.55%)
BAC   23.38 (+5.55%)
GILD   74.69 (+0.03%)
DIS   100.76 (-0.47%)
S&P 500   2,750.62 (+3.43%)
DOW   23,433.16 (+3.44%)
QQQ   200.69 (+2.18%)
AAPL   266.43 (+2.70%)
FB   174.04 (+3.08%)
MSFT   165.68 (+1.34%)
GOOGL   1,211.37 (+2.44%)
AMZN   2,036.99 (+1.26%)
CGC   15.13 (+4.34%)
BABA   195.05 (-1.49%)
MU   48.36 (+3.89%)
GE   7.30 (+3.84%)
TSLA   546.97 (+0.28%)
AMD   48.83 (+2.67%)
T   29.72 (-1.20%)
ACB   0.87 (+7.45%)
NFLX   370.81 (-0.55%)
BAC   23.38 (+5.55%)
GILD   74.69 (+0.03%)
DIS   100.76 (-0.47%)
Log in

NYSE:ABBVAbbVie Stock Price, Forecast & News

$78.73
+3.34 (+4.43 %)
(As of 04/8/2020 03:16 PM ET)
Add
Compare
Today's Range
$74.78
Now: $78.73
$78.91
50-Day Range
$64.50
MA: $81.90
$94.96
52-Week Range
$62.55
Now: $78.73
$97.86
Volume6.41 million shs
Average Volume16.68 million shs
Market Capitalization$116.26 billion
P/E Ratio14.91
Dividend Yield6.43%
Beta0.84
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; and Calico Life Sciences LLC. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More
AbbVie logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.9Dividend Strength: 5.0Insider Behavior: 4.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

3.27 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP00287Y10
Phone847-932-7900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$33.27 billion
Cash Flow$11.09 per share
Book Value($5.53) per share

Profitability

Net Income$7.88 billion

Miscellaneous

Employees30,000
Outstanding Shares1,476,670,000
Market Cap$116.26 billion
Next Earnings Date5/1/2020 (Confirmed)
OptionableOptionable

Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.


AbbVie (NYSE:ABBV) Frequently Asked Questions

How has AbbVie's stock been impacted by COVID-19 (Coronavirus)?

AbbVie's stock was trading at $84.85 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ABBV stock has decreased by 7.8% and is now trading at $78.22. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of AbbVie?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 6 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for AbbVie.

When is AbbVie's next earnings date?

AbbVie is scheduled to release its next quarterly earnings announcement on Friday, May 1st 2020. View our earnings forecast for AbbVie.

How can I listen to AbbVie's earnings call?

AbbVie will be holding an earnings conference call on Friday, May 1st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were AbbVie's earnings last quarter?

AbbVie Inc (NYSE:ABBV) posted its quarterly earnings results on Friday, February, 7th. The company reported $2.21 EPS for the quarter, topping the consensus estimate of $2.19 by $0.02. The company earned $8.70 billion during the quarter, compared to analysts' expectations of $8.68 billion. AbbVie had a negative return on equity of 162.54% and a net margin of 23.69%. The business's revenue was up 4.8% compared to the same quarter last year. During the same period last year, the company posted $1.90 earnings per share. View AbbVie's earnings history.

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie declared a quarterly dividend on Thursday, February 20th. Investors of record on Wednesday, April 15th will be paid a dividend of $1.18 per share on Friday, May 15th. This represents a $4.72 dividend on an annualized basis and a dividend yield of 6.03%. The ex-dividend date of this dividend is Tuesday, April 14th. View AbbVie's dividend history.

How will AbbVie's stock buyback program work?

AbbVie declared that its board has authorized a stock buyback plan on Thursday, December 13th 2018, which allows the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to repurchase up to 3.8% of its shares through open market purchases. Shares buyback plans are often a sign that the company's board believes its stock is undervalued.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie updated its FY20 earnings guidance on Friday, February, 7th. The company provided EPS guidance of $9.61-9.71 for the period, compared to the Thomson Reuters consensus estimate of $9.78.

What price target have analysts set for ABBV?

14 Wall Street analysts have issued 1 year target prices for AbbVie's stock. Their forecasts range from $78.00 to $105.00. On average, they anticipate AbbVie's stock price to reach $91.83 in the next year. This suggests a possible upside of 17.4% from the stock's current price. View analysts' price targets for AbbVie.

Has AbbVie been receiving favorable news coverage?

Media coverage about ABBV stock has trended very negative on Wednesday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AbbVie earned a news impact score of -3.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutAbbVie.

Who are some of AbbVie's key competitors?

What other stocks do shareholders of AbbVie own?

Who are AbbVie's key executives?

AbbVie's management team includes the following people:
  • Mr. Richard A. Gonzalez, Chairman & CEO (Age 65)
  • Dr. Michael E. Severino, Vice Chairman & Pres (Age 53)
  • Mr. Robert A. Michael, Sr. VP & CFO (Age 49)
  • Mr. William J. Chase, Exec. VP of Fin. & Admin. (Age 51)
  • Ms. Laura J. Schumacher, Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec. (Age 56)

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

Who are AbbVie's major shareholders?

AbbVie's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.02%), Park National Corp OH (0.01%), Thomasville National Bank (0.01%), CLARET ASSET MANAGEMENT Corp (0.01%), Cypress Capital Group (0.01%) and Gradient Investments LLC (0.01%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Roxanne S Austin, Timothy J Richmond and William J Chase. View institutional ownership trends for AbbVie.

Which institutional investors are selling AbbVie stock?

ABBV stock was sold by a variety of institutional investors in the last quarter, including Park National Corp OH, Private Trust Co. NA, CLARET ASSET MANAGEMENT Corp, Cullinan Associates Inc., American National Bank, Pensionfund DSM Netherlands, Blackhawk Capital Partners LLC., and First National Bank of Mount Dora Trust Investment Services. View insider buying and selling activity for AbbVie.

Which institutional investors are buying AbbVie stock?

ABBV stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, IBM Retirement Fund, Polianta Ltd, Neville Rodie & Shaw Inc., Spirit of America Management Corp NY, Red Spruce Capital LLC, IMS Capital Management, and Sound Income Strategies LLC. Company insiders that have bought AbbVie stock in the last two years include Brian L Durkin, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin, and William J Chase. View insider buying and selling activity for AbbVie.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $78.22.

How big of a company is AbbVie?

AbbVie has a market capitalization of $115.51 billion and generates $33.27 billion in revenue each year. The company earns $7.88 billion in net income (profit) each year or $8.94 on an earnings per share basis. AbbVie employs 30,000 workers across the globe. View additional information about AbbVie.

What is AbbVie's official website?

The official website for AbbVie is http://www.abbvie.com/.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.

This page was last updated on 4/8/2020 by MarketBeat.com Staff

Featured Article: Cost of Goods Sold (COGS)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel